Disease diagnostics involvesvarious laboratory techniques for identification of test samples such as bloodand urine for identification and quantification of infective agents. Providingdiagnosis based only on symptoms is challenging, as two or more diseases canexhibit similar symptoms and therefore diagnostic tests are used forconfirmation of the disease. Diagnostic tests provide rapid and preciseresults, thereby saving time and providing physicians ample time for treatment.
The global InfectiousDisease Diagnostics Market is estimated to account for US$ 1,131.4 Mn interms of value in 2020 and is expected to reach US$ 1,841.2 Mn by the end of2027.
Global Infectious DiseaseDiagnostics Market: Drivers
Initiatives to address diagnosticchallenges in emerging economies is expected to propel growth of the globalinfectious disease diagnostics market over the forecast period. For instance,in January 2018, The Foundation for Innovative New Diagnostics collaboratedwith Becton, Dickinson, and Company (BD), Fondation Botnar, the GlobalAntibiotic Research & Development Partnership (GARDP), the Drugs forNeglected Diseases Initiative (DNDi), and the South African Medical ResearchCouncil (SAMRC) to address antimicrobial resistance (AMR) by accelerating theuse of diagnostics.
Global Infectious Disease DiagnosticsMarket: Opportunities
Public and private initiatives tocurb infectious diseases is expected to offer lucrative growth opportunitiesfor players in the market. For instance, in February 2020, Department of Healthand Human Services announced a federal grant of US$ 750,000 to the city ofAustin to help fight the spread of HIV/AIDS in Texas, U.S.
Global Infectious DiseaseDiagnostics Market: Restraints
Low awareness and adoption ofdiagnostic services in emerging economies is expected to hinder growth of themarket. For instance, according to GLOBAL AIDS UPDATE 2019 of UNAIDS, inMadagascar, Mauritius, and South Sudan, fewer than 25% of people living withHIV are aware of their status.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1971
Key Takeaways:
The cell cultures segment in theglobal infectious disease diagnostics market was valued at US$ 362.3 Mn in 2018and is expected to reach US$ 747.4 Mn by 2027 at a CAGR of 8.3% during theforecast period. Several types of infections can be diagnosed using cellculture, where, microbes are grown in a laboratory setting to identify thesame.
The STDs segment held dominantposition in the global infectious disease diagnostics market in 2018,accounting for 32.8% share in terms of value, followed by CNS infection, andrespiratory infections, respectively. Increasing sexually transmitted diseaseburden is fueling growth of the segment. Among 20 STDs, the most common areGonorrhea, Chlamydia, Syphilis, Herpes, Hepatitis (HBV), and HumanImmunodeficiency Virus (HIV). For instance, according to Centers for DiseaseControl and Prevention (CDC), in year 2016, 1,598,354 cases of Chlamydiatrachomatis infection were reported in the U.S., corresponding to 497.3 casesper 100,000 in 2015.
Diagnostic centers segment in theglobal infectious disease diagnostics market was valued at US$ 462.1 Mn in 2018and is expected to reach US$ 958.7 Mn by 2027 at a CAGR of 8.5% during theforecast period. Central diagnostic laboratories are well equipped with latestdiagnostic instruments, and have large resources to carry out multiple tests.Large number of tests are carried out on a daily basis in these centers which supportsgrowth of the segment.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/infectious-disease-diagnostics-market-1971
Market Trends
Limited specificity of diagnostictests available for infectious diseases triggers the need for combineddiagnosis, which includes multiple tests. The trend of diagnosing a diseasethrough multiple tests is gaining popularity.
The market in North America isexpected to witness significant growth, owing to increasing healthcareexpenditure. For instance, according to the Centers for Medicare & MedicaidServices (CMS), health spending in the U.S. is projected to grow at an averagerate of 5.5 percent per year for 2018-27 and to reach nearly US$ 6.0 trillionby 2027. However, the reimbursement scenario for diagnostic tests iscomparatively poorer.
Global Infectious DiseaseDiagnostics Market: Competitive Landscape
Major players operating in theglobal infectious disease diagnostics market include, Becton Dickinson &Company, Cepheid, Inc., Abbott Laboratories, BioMerieux SA, Hologic, Inc.,Danaher Corporation, Thermo Fisher Scientific, Inc., Roche Diagnostics, AleraInc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.
Global Infectious Disease DiagnosticsMarket: Key Developments
March 2020: Chembio Diagnostics,Inc., a point-of-care diagnostics company focused on infectious diseases,completed the technical feasibility phase for a potential companion/compatiblediagnostic test being developed in collaboration with Shire Human GeneticTherapies, Inc., a wholly owned subsidiary of Takeda Pharmaceutical CompanyLimited
March 2020: GenMark Diagnostics,Inc., a provider of automated, multiplex molecular diagnostic testing systems,submitted an Emergency Use Authorization to the U.S. Food and DrugAdministration (FDA) for its ePlex SARS-CoV-2 Test
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1971
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
